证券日报网讯12月1日，透景生命（300642）在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东总户数18785户。 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-089 上海透景生命科技股份有限公司 关于申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"）全资 子公司江西透景生命科技有限公司（以下简称"江西透景"或"全资子公司"） 申报的医疗器械注册申请于近期获得了江西省药品监督管理局的受理，具体情况 如下： | 1 | 全自动流式荧光发光免疫分析仪 型号：TESMI F5000、TESMI F5000M | 第二类体外 诊断仪器 | 本产品基于藻红蛋白的流 式荧光发光法，与配套的检 | | --- | --- | --- | --- | | 序号 | 产品名称 | 注册分类 | 预期用途 测试剂共同使用，在临床上 | 一、基本信息 二、产品的基本情况 上述产品 1-2 系全自动流式荧光发光免疫分析仪，上述产品 3-4 系全自动化 学发光免疫分析仪，在其各自的控制系统中可编制所需的实验处理控制过程，系 统根据给定的控制过程，自动进行调度执行，快速完成相应的试验。 本次 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-087 上海透景生命科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议届次：2025 年第一次临时股东大会 2、会议召集人：上海透景生命科技股份有限公司（以下简称"公司"或"透 景生命"）董事会 二、议案审议表决情况 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和 国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 27 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 27 日 9:15-9:25，9:30-11:30，13:00-1 ...

上海透景生命科技股份有限公司 证券代码：300642 证券简称：透景生命 公告编号：2025-088 关于非独立董事辞任及选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、辞任报告； 一、非独立董事辞任情况 公司董事会于近日收到董事、副总经理、董事会秘书王小清先生提交的书面 辞任报告，因《公司章程》等内部制度调整，王小清先生申请辞去公司非独立董 事职务，辞任后仍继续担任公司副总经理、董事会秘书。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《公司章程》 等有关规定，王小清先生辞任非独立董事是根据修订后的《公司章程》对公司董 事会席位结构做出的正常调整，不影响公司董事会及董事会专门委员会的正常运 行，不会对公司正常经营产生不利影响，其辞任报告自送达董事会之日起生效。 王小清先生非独立董事职务的原定任期至第四届董事会届满之日止。截至本 公告披露日，王小清先生持有公司股份 8,620 股（含已授予尚未解除限售的限制 性股票 6,000 股），其所持股份将继续严格按照《公司法》《上市公司董事和高 级管理人员所持本公司股份及其变动管 ...

为出具法律意见书，本律师审查了公司提供的有关召集、召开本 次股东大会的文件材料,并出席本次股东大会进行现场见证。 在法律意见书中，本律师根据法律意见书出具日以前发生的事实 及对该事实的了解，对公司本次股东大会所涉及的法律问题发表法律 意见,并依法对法律意见书承担责任。 本律师同意，公司可以将法律意见书作为本次股东大会的法定文 件,随同本次股东大会决议一并公告。 关于上海透景生命科技股份有限公司 2025 年第一次临时股东大会 法 律 意 见 书 致：上海透景生命科技股份有限公司 上海市光大律师事务所接受上海透景生命科技股份有限公司（以 下简称"公司"）的委托，指派潘轶、程安卿律师（以下简称"本律 师"）就公司于 2025 年 11 月 27 日召开的 2025 年第一次临时股东大 会（以下简称"本次股东大会"）相关事宜，根据《中华人民共和国 公司法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下 简称"规范性文件"）和《上海透景生命科技股份有限公司章程》（以 下简称"公司章程"）的规定，出具法律意见书。 为召开本次股东大会，公司董事会 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, but the revenue decline in Q3 showed notable improvement compared to earlier quarters, indicating a gradual recovery from the impact of centralized procurement [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 258 million yuan, down 19.73% year-on-year, with a net profit attributable to shareholders of 6 million yuan, down 76.33% [1]. - In Q3 2025, the company reported a revenue of 99 million yuan, a decrease of 6.36% year-on-year, and a net profit of 3 million yuan, down 83.02% [1]. Impact of Centralized Procurement - The revenue decline is primarily attributed to the impact of centralized procurement and market conditions, but the decline rate in Q3 has significantly narrowed to -6.36% from -26.25% in the first half of the year [2]. - The company expects the negative effects of centralized procurement to gradually diminish within 2025, as revenues from key products like tumor markers and HPV testing are showing signs of recovery [2]. Business Expansion - The company has accelerated its business expansion, completing the integration of its subsidiary Hebei Toukang, which allows entry into the invasive fungal disease testing market [3]. - The company announced plans to acquire Kanglu Bio, a leader in the pathology diagnosis sector, which will enhance its capabilities in molecular pathology technologies [3]. - A strategic investment in Huihe Bio is aimed at strengthening the company's position in the autoimmune disease diagnosis and treatment sector, creating a comprehensive "diagnosis-treatment-monitoring" chain [3]. Research and Development - The company maintains a high R&D expense ratio of 15.52% for the first three quarters of 2025, increasing to 17.16% in Q3, indicating a strong commitment to R&D [4]. - Several new reagent products have received medical device registration certificates, enhancing the company's product offerings in various fields, including autoimmune and coagulation testing [4].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 25 yuan [2][8]. Core Insights - The company is gradually overcoming the impact of centralized procurement, with business expansion accelerating. The revenue for the first three quarters of 2025 was 258 million yuan, a decrease of 19.73% year-on-year, while the net profit attributable to shareholders was 6 million yuan, down 76.33% [2][8]. - In Q3 2025, the revenue was 99 million yuan, a decline of 6.36% year-on-year, indicating a significant improvement compared to the first half of the year [2][8]. - The company has completed the integration of its subsidiary, Hebei Toukeng, and is entering the invasive fungal disease detection field, which fills a gap in its product offerings [8]. Financial Performance Summary - The total revenue forecast for 2024A is 437 million yuan, with a year-on-year growth rate of -19.5%. For 2025E, the revenue is expected to be 383 million yuan, with a growth rate of -12.4%. By 2026E, the revenue is projected to increase to 469 million yuan, reflecting a growth rate of 22.4% [4][9]. - The net profit attributable to shareholders is forecasted to be 34 million yuan in 2024A, dropping to 9 million yuan in 2025E, and then rising to 41 million yuan in 2026E, with a significant growth rate of 371.7% [4][9]. - The company maintains a high R&D expense ratio, with 15.52% for the first three quarters of 2025 and 17.16% for Q3 2025, indicating a commitment to innovation and product development [8]. Business Expansion and Product Development - The company is actively pursuing mergers and acquisitions to enhance its competitive edge in the tumor diagnosis field, including the acquisition of Kanglu Bio, a leader in the pathology diagnosis segment [8]. - New product lines in autoimmune, metabolic, hormone, and lung cancer methylation testing are contributing to revenue growth, alongside the integration of external acquisitions [8]. - The company has received medical device registration certificates for several new reagents, enhancing its product pipeline and market offerings [8].

（文章来源：证券日报） 证券日报网讯 11月18日晚间，透景生命发布公告称，上海透景生命科技股份有限公司（以下简称"公 司"或"透景生命"）基于长期战略发展规划，与惠和生物技术（上海）有限公司（以下简称"惠和生 物"）、上海欣百诺生物科技有限公司、上海路思何企业管理合伙企业（有限合伙）、朱化星、黄应峰 等分别签署《关于惠和生物技术（上海）有限公司之增资协议》（以下简称"《增资协议》"）和《关于 惠和生物技术（上海）有限公司之股东协议》（以下简称"《股东协议》"，与《增资协议》单独或合 称"《协议》"），约定以自有资金人民币6，800万元认购惠和生物新增注册资本人民币17.5992万元。 本次投资完成后，公司将持有惠和生物9.2141%的股权。截至本公告披露日，本次交易各方已根据《协 议》的约定完成了全部交割工作。 ...

Core Viewpoint - The company, Transgen Life (300642.SZ), has received a change registration document from the National Medical Products Administration for its "Human Papillomavirus Nucleic Acid Detection and Genotyping Kit (Fluorescent PCR Method)" [1] Group 1: Product Changes - The company has completed changes related to the original registration certificate of the HPV detection kit, which now includes three new intended uses: cervical cancer primary screening, combined screening, and ASC-US triage [1] - The changes in the medical device registration are expected to better meet the diverse testing needs of end customers [1] Group 2: Market Impact - The acquisition of the medical device change registration certificate is anticipated to enhance the company's market expansion capabilities [1] - The positive impact on the company's future production and operations is highlighted as a result of these changes [1]